The role of KRAS rs61764370 in invasive epithelial ovarian cancer: Implications for clinical testing

PDP Pharoah; RT Palmieri; SJ Ramus; SA Gayther; IL Andrulis; H Anton-Culver; N Antonenkova; AC Antoniou; D Goldgar; MS Beattie; MW Beckmann; MJ Birrer; N Bogdanova; KL Bolton; W Brewster; A Brooks-Wilson; R Brown; R Butzow; T Caldes; MA Caligo; I Campbell; J Chang-Claude; YA Chen; LS Cook; FJ Couch; DW Cramer; JM Cunningham; E Despierre; JA Doherty; T Dörk; M Dürst; DM Eccles; AB Ekici; D Easton; PA Fasching; A De Fazio; DA Fenstermacher; JM Flanagan; BL Fridley; E Friedman; B Gao; O Sinilnikova; A Gentry-Maharaj; AK Godwin; EL Goode; MT Goodman; J Gross; TVO Hansen; P Harnett; M Rookus; T Heikkinen; R Hein; C Høgdall; E Høgdall; ES Iversen; A Jakubowska; SE Johnatty; BY Karlan; ND Kauff; SB Kaye; G Chenevix-Trench; LE Kelemen; LA Kiemeney; SK Kjaer; D Lambrechts; JP LaPolla; C Lázaro; ND Le; A Leminen; K Leunen; DA Levine; Y Lu; L Lundvall; S Macgregor; T Marees; LF Massuger; JR McLaughlin; U Menon; M Montagna; KB Moysich; SA Narod; KL Nathanson; L Nedergaard; RB Ness; H Nevanlinna; S Nickels; A Osorio; J Paul; CL Pearce; CM Phelan; MC Pike; P Radice; MA Rossing; JM Schildkraut; TA Sellers; CF Singer; H Song; DO Stram; R Sutphen; A Lindblom

Journal article

The role of KRAS rs61764370 in invasive epithelial ovarian cancer: Implications for clinical testing

PDP Pharoah, RT Palmieri, SJ Ramus, SA Gayther, IL Andrulis, H Anton-Culver, N Antonenkova, AC Antoniou, D Goldgar, MS Beattie, MW Beckmann, MJ Birrer, N Bogdanova, KL Bolton, W Brewster, A Brooks-Wilson, R Brown, R Butzow, T Caldes, MA Caligo Show all

Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2011

DOI: 10.1158/1078-0432.CCR-10-3405

Abstract

Purpose: An assay for the single-nucleotide polymorphism (SNP), rs61764370, has recently been commercially marketed as a clinical test to aid ovarian cancer risk evaluation in women with family histories of the disease. rs67164370 is in a 3′-UTR miRNA binding site of the KRAS oncogene and is a candidate for epithelial ovarian cancer (EOC) susceptibility. However, only one published article, analyzing fewer than 1,000 subjects in total, has examined this association. Experimental Design: Risk association was evaluated in 8,669 cases of invasive EOC and 10,012 controls from 19 studies participating in the Ovarian Cancer Association Consortium, and in 683 cases and 2,044 controls carrying BRCA1..

View full abstract

University of Melbourne Researchers

Ian Campbell Author

Related Projects (1)

NIH AUSTRALIAN BREAST CANCER FAMILY REGISTRY SOUTHEY-HOPPER

DESCRIPTION (provided by applicant): The broad objective of the Breast Cancer Family Registry (Breast CFR) is to establish and maintain a hy..

Grants

Awarded by National Cancer Institute

Funding Acknowledgements

The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund. Funding for the individual participating studies was provided by: cooperative agreements with the Breast Cancer Family Registry including Cancer Care Ontario, and US NIH grants 5U01-CA069467, 5U01-CA069398, 5U01-CA069631, 5U01-CA069446, 5U01-CA069417, 5U01-CA069638, and N02-PC45022 (BCFR); the National Cancer Plan-Action 29 for the support of Translational Research (BEL); NIH grants 5R01-CA054419 and 5P50-CA105009 (BWH); NIH grants 5R01-CA112523 and 5R01-CA087538 (DOV); the Ligue National Contre le Cancer, the Association "Le cancer du sein, parlonsen!" and research grant AICR-07-0454 from the Association for International Cancer Research (GEMO); the German Federal Ministry of Education and Research, the Programme of Clinical Biomedical Research grant 01 GB 9401, the state of Baden-Wurttemberg through the University of Ulm Medical Faculty grant P.685, and the German Cancer Research Center (GER); the Helsinki University Central Hospital Research Fund, Academy of Finland and the Finnish Cancer Society (HOC); NIH grants 5R01-CA095023, 5R01-CA126841, and 5R03-CA121881, US Army MRMC grant DAMD 17-02-1-0669, and grants from the Ovarian Cancer Research Foundation and the Roswell Park Alliance Foundation (HOP); grant 628333 from Cancer Australia and grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia (kConFab); American Cancer Society Early Detection Professorship grant SIOP-06-258-01-CCE and the L & S Milken Foundation (LAX); Mermaid 1, The Danish Cancer Society and the National Cancer Institute 5R01-CA061107 (MAL); National Cancer Institute 5R01-CA122443 (MAY); National Cancer Institute 5R01-CA076016 (NCO); an Investment Grant of the Radboud University Nijmegen Medical Centre (NTH); grants from the Canadian Institutes of Health Research (CIHR) and the Workers' Compensation Board of British Columbia (OVA); Cancer Research UK (SEA); Experimental Cancer Research Centres and Cancer Research UK A6689 (SRO); NIH grant 5R01-CA106414, American Cancer Society grant CRTG-00-196-01-CCE and an Advanced Cancer Detection Center Grant, Department of Defense grant DAMD 17-98-1-8659, and funding from the Celma Mastry Ovarian Cancer Foundation (TBO); Canadian Institutes for Health Research, the National Cancer Institute of Canada, the Canadian Cancer Society and the NIH grants 5R01-CA063682 and 5R01-CA063678 (TOR); National Cancer Institute grants 5R01-CA058860 and 5K07-CA092044 and the Lon V Smith Foundation LVS-39420 (UCI); Cancer Research UK, the Eve Appeal, the OAK Foundation and the Department of Health's NIHR Biomedical Research Centre funding scheme (UKO); the California Cancer Research Program grants 00-01389V-20170 and 2110200, NIH grants 5P30-CA014089, 5P01-CA017054, 5R01-CA061132, 5R01-CA063464, N01-PC67010, and 5R03-CA113148, and California Department of Health Services sub-contract 050-E8709 (USC); Wellcome Trust award 076113 (WTCCC). Additional support for the TOR, NCO, MAY, TBO, and NCI studies was provided by NIH grant 5R01-CA114343. The Consortium of Investigators of Modifiers of BRCA1/2 GWAS and its participating studies were funded by: the Breast Cancer Research Foundation, Susan G. Komen for the Cure, the Ovarian Cancer Research Fund, the Eileen Stein Jacoby Fund, NIH grants 5R01-CA128978 and 1R01-CA140323, Cancer Research UK, he Neve Foundation, Project Hope for Ovarian Cancer Research and Education, the Australian National Breast Cancer Foundation, the National Health and Medical Research Council of Australia.